Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$2.94 USD
+0.01 (0.36%)
Updated Aug 6, 2024 03:39 PM ET
After-Market: $3.00 +0.06 (2.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LSTA 2.94 +0.01(0.36%)
Will LSTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSTA
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
Other News for LSTA
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
Lisata Therapeutics treatment of cholangiocarcinoma granted FDA orphan status
Lisata Therapeutics: A Strong Buy on Revolutionary Cancer Treatment Advancements
Lisata to use Haystack technology to evaluate pancreatic cancer asset certepetide
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD? Technology to Evaluate Efficacy of Pancreatic Cancer Therapy